8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Jan 20, 2026·SEC
Material company update
Jan 14, 2026·SEC
RAPT Therapeutics, Inc.(RAPT)Earnings, Financials & Key Ratios
RAPT•NASDAQ
Price updated Apr 24, 2026
AboutRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$135M-7.2%
- Net Income-$130M-11.2%
- EPS (Diluted)-25.49-4.6%
- ROE-77.09%-29.4%
RAPT Key Insights
RAPT Therapeutics, Inc. (RAPT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RAPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RAPT Price & Volume
RAPT Therapeutics, Inc. (RAPT) stock price & volume — 10-year historical chart
Loading chart...
RAPT Growth Metrics
RAPT Therapeutics, Inc. (RAPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.24%
Return on Capital
10 Years-59.56%
5 Years-57.23%
3 Years-60.38%
Last Year-79.25%
RAPT Recent Earnings
RAPT Therapeutics, Inc. (RAPT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
Mar 5, 2026Metric
Actual
Est
EPS
$9.12-1008.2%
$0.82
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.65+26.1%
$0.88
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.65-6.6%
$0.61
Rev
—
—
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$0.64+74.2%
$2.48
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $9.12vs $0.82-1008.2% | — |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.88+26.1% | — |
| Q3 2025 | Aug 7, 2025 | $0.65vs $0.61-6.6% | — |
| Q2 2025 | May 8, 2025 | $0.64vs $2.48+74.2% | — |
Based on last 12 quarters of dataView full earnings history →
RAPT Peer Comparison
RAPT Therapeutics, Inc. (RAPT) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 |
Compare RAPT vs Peers
RAPT Therapeutics, Inc. (RAPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RAPT Income Statement
RAPT Therapeutics, Inc. (RAPT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 5.04M | 3.81M | 1.53M | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | -24.38% | -59.95% | -100% | - | - |
Cost of Goods Sold | 1.38M | 1.24M | 1.33M | 0 | 0 | 0 | 0 | 0 | 200K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -1.38M▲ 0% | -1.24M▲ 10.6% | -1.33M▼ 7.5% | 5.04M▲ 479.1% | 3.81M▼ 24.4% | 1.53M▼ 60.0% | 0▼ 100.0% | 0▲ 0% | -200K▲ 0% |
Gross Margin % | - | - | - | 100% | 100% | 100% | - | - | - |
Gross Profit Growth % | - | 10.62% | -7.52% | 479.1% | -24.38% | -59.95% | -100% | - | - |
Operating Expenses | 29.33M | 36.95M | 43.63M | 58.26M | 73.02M | 87.32M | 127.06M | 136.1M | 112.44M |
OpEx % of Revenue | - | - | - | 1155.41% | 1915.08% | 5718.53% | - | - | - |
Selling, General & Admin | 3.71M | 5.18M | 8.72M | 12.77M | 16.04M | 20.24M | 26.06M | 28.88M | 29.76M |
SG&A % of Revenue | - | - | - | 253.29% | 420.59% | 1325.47% | - | - | - |
Research & Development | 25.62M | 31.77M | 34.91M | 45.48M | 56.98M | 67.08M | 101M | 107.22M | 82.87M |
R&D % of Revenue | - | - | - | 902.12% | 1494.49% | 4393.06% | - | - | - |
Other Operating Expenses | 216K | 800K | 1.29M | 0 | 0 | 0 | 0 | 0 | -200K |
Operating Income | -29.33M▲ 0% | -36.95M▼ 26.0% | -43.63M▼ 18.1% | -53.21M▼ 22.0% | -69.21M▼ 30.1% | -85.8M▼ 24.0% | -127.06M▼ 48.1% | -136.1M▼ 7.1% | -112.64M▲ 0% |
Operating Margin % | - | - | - | -1055.41% | -1815.08% | -5618.53% | - | - | - |
Operating Income Growth % | - | -25.97% | -18.09% | -21.97% | -30.06% | -23.97% | -48.1% | -7.11% | - |
EBITDA | -27.95M | -35.71M | -42.3M | -52.09M | -68.21M | -84.75M | -125.85M | -134.9M | -111.69M |
EBITDA Margin % | - | - | - | -1033.14% | -1788.96% | -5549.97% | - | - | - |
EBITDA Growth % | - | -27.78% | -18.45% | -23.15% | -30.95% | -24.24% | -48.49% | -7.19% | 1.69% |
D&A (Non-Cash Add-back) | 1.38M | 1.24M | 1.33M | 1.12M | 996K | 1.05M | 1.22M | 1.2M | 944K |
EBIT | -29.33M | -36.95M | -43.63M | -53.21M | -69.21M | -85.8M | -127.06M | -136.1M | -108.95M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 216K | 800K | 1.29M | 1.31M | 5K | 1.96M | 10.26M | 6.24M | 7M |
Pretax Income | -29.11M▲ 0% | -36.15M▼ 24.2% | -42.34M▼ 17.1% | -51.9M▼ 22.6% | -69.2M▼ 33.3% | -83.84M▼ 21.1% | -116.8M▼ 39.3% | -129.87M▼ 11.2% | -105.64M▲ 0% |
Pretax Margin % | - | - | - | -1029.39% | -1814.95% | -5490.37% | - | - | - |
Income Tax | 0 | 0 | 660K | 990K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | -1.56% | -1.91% | 0% | 0% | 0% | 0% | 0% |
Net Income | -29.11M▲ 0% | -36.15M▼ 24.2% | -43M▼ 19.0% | -52.89M▼ 23.0% | -69.2M▼ 30.8% | -83.84M▼ 21.1% | -116.8M▼ 39.3% | -129.87M▼ 11.2% | -105.64M▲ 0% |
Net Margin % | - | - | - | -1049.03% | -1814.95% | -5490.37% | - | - | - |
Net Income Growth % | - | -24.15% | -18.95% | -23.01% | -30.84% | -21.15% | -39.31% | -11.19% | 1.73% |
Net Income (Continuing) | -29.11M | -36.15M | -43M | -52.89M | -69.2M | -83.84M | -116.8M | -129.87M | -105.64M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -10.95▲ 0% | -13.59▼ 24.2% | -15.75▼ 15.9% | -17.53▼ 11.3% | -20.21▼ 15.3% | -20.61▼ 2.0% | -24.37▼ 18.2% | -25.49▼ 4.6% | -3.92▲ 0% |
EPS Growth % | - | -24.15% | -15.94% | -11.28% | -15.29% | -1.97% | -18.25% | -4.58% | 50.24% |
EPS (Basic) | -10.95 | -13.59 | -15.75 | -17.53 | -20.21 | -20.61 | -24.37 | -25.49 | - |
Diluted Shares Outstanding | 2.66M | 2.66M | 2.73M | 3.02M | 3.42M | 4.07M | 4.79M | 5.1M | 26.96M |
Basic Shares Outstanding | 2.66M | 2.66M | 2.73M | 3.02M | 3.42M | 4.07M | 4.79M | 5.1M | 26.96M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RAPT Balance Sheet
RAPT Therapeutics, Inc. (RAPT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 48.24M | 65.06M | 80.51M | 115.6M | 192.97M | 252.69M | 161.78M | 235.24M | 161.04M |
Cash & Short-Term Investments | 47.52M | 63.8M | 77.38M | 111.51M | 189.65M | 249.07M | 158.86M | 231.06M | 157.34M |
Cash Only | 47.52M | 63.8M | 77.38M | 24.92M | 24.03M | 38.95M | 47.48M | 169.74M | 37.93M |
Short-Term Investments | 0 | 0 | 0 | 86.59M | 165.63M | 210.12M | 111.38M | 61.32M | 119.41M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 4.09M | 3.32M | 3.63M | 2.92M | 4.18M | 3.7M |
Total Non-Current Assets | 2.15M | 4.55M | 4.1M | 3.37M | 5.66M | 13.52M | 11.55M | 5.09M | 4.69M |
Property, Plant & Equipment | 1.91M | 4.16M | 3.71M | 2.98M | 2.74M | 9.48M | 7.68M | 4.7M | 2.65M |
Fixed Asset Turnover | - | - | - | 1.69x | 1.39x | 0.16x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 605K | 598K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -369K | -209K | 389K | 389K | 2.92M | 4.04M | 3.87M | 389K | 2.05M |
Total Assets | 50.39M▲ 0% | 69.61M▲ 38.1% | 84.6M▲ 21.5% | 118.97M▲ 40.6% | 198.64M▲ 67.0% | 266.21M▲ 34.0% | 173.33M▼ 34.9% | 240.32M▲ 38.7% | 165.74M▲ 0% |
Asset Turnover | - | - | - | 0.04x | 0.02x | 0.01x | - | - | 0.00x |
Asset Growth % | - | 38.14% | 21.54% | 40.62% | 66.96% | 34.02% | -34.89% | 38.65% | 152.12% |
Total Current Liabilities | 3.25M | 4.64M | 9.26M | 11.74M | 9.6M | 14.22M | 21.84M | 48.35M | 13.38M |
Accounts Payable | 1.11M | 1.77M | 1.14M | 2.38M | 2M | 3.37M | 5.18M | 1.27M | 2.1M |
Days Payables Outstanding | 291.68 | 522.57 | 313.68 | - | - | - | - | - | 4.04K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.21M |
Deferred Revenue (Current) | 0 | 0 | 4M | 4.1M | 1.02M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 650K | 586K | 2.25M | 2.3M | 2.93M | 4.65M | 7.91M | 6.78M | 9.06M |
Current Ratio | 14.85x | 14.01x | 8.70x | 9.84x | 20.11x | 17.77x | 7.41x | 4.87x | 12.04x |
Quick Ratio | 14.85x | 14.01x | 8.70x | 9.84x | 20.11x | 17.77x | 7.41x | 4.87x | 12.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 109.55M | 969K | 2.23M | 3.05M | 2.66M | 6.82M | 4.46M | 2.07M | 387K |
Long-Term Debt | 108.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 387K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 6.82M | 4.46M | 2.07M | 4.55M |
Deferred Tax Liabilities | -108.64M | -162.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 905K | 969K | 2.23M | 2.19M | 2.15M | 0 | 0 | 0 | 0 |
Total Liabilities | 112.8M | 5.61M | 11.48M | 14.79M | 12.26M | 21.04M | 26.29M | 50.42M | 13.76M |
Total Debt | 108.64M | 161.11M | 0 | 0 | 0 | 8.99M | 6.91M | 4.49M | 2.6M |
Net Debt | 61.13M | 97.31M | -77.38M | -24.92M | -24.03M | -29.96M | -40.57M | -165.24M | -35.33M |
Debt / Equity | - | 2.52x | - | - | - | 0.04x | 0.05x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.32x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -62.41M▲ 0% | 64M▲ 202.6% | 73.12M▲ 14.3% | 104.18M▲ 42.5% | 186.38M▲ 78.9% | 245.17M▲ 31.5% | 147.03M▼ 40.0% | 189.9M▲ 29.2% | 151.98M▲ 0% |
Equity Growth % | - | 202.55% | 14.26% | 42.47% | 78.9% | 31.54% | -40.03% | 29.16% | 174.38% |
Book Value per Share | -23.46 | 24.06 | 26.79 | 34.53 | 54.44 | 60.27 | 30.68 | 37.27 | 5.64 |
Total Shareholders' Equity | -62.41M | 64M | 73.12M | 104.18M | 186.38M | 245.17M | 147.03M | 189.9M | 151.98M |
Common Stock | 1K | 2K | 2K | 2K | 3K | 3K | 3K | 13K | 2K |
Retained Earnings | -82.81M | -118.95M | -161.95M | -214.84M | -284.05M | -367.88M | -484.68M | -614.55M | -666.93M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3.77M | -4K | 20K | -177K | -206K | -26K | 103K | 50K | 100K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RAPT Cash Flow Statement
RAPT Therapeutics, Inc. (RAPT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -27.12M | -32.95M | -35.47M | -40.49M | -61.03M | -70.77M | -97.05M | -83.3M | -86.58M |
Operating CF Margin % | - | - | - | -803.07% | -1600.47% | -4634.64% | - | - | - |
Operating CF Growth % | - | -21.49% | -7.65% | -14.14% | -50.71% | -15.97% | -37.13% | 14.17% | 58.14% |
Net Income | -29.11M | -36.15M | -43M | -52.89M | -69.2M | -83.84M | -116.8M | -129.87M | -105.64M |
Depreciation & Amortization | 1.38M | 1.24M | 1.33M | 1.12M | 996K | 1.05M | 3.55M | 1.2M | 972K |
Stock-Based Compensation | 716K | 1.17M | 2.05M | 8.69M | 9.95M | 11.26M | 0 | 19.93M | 18.8M |
Deferred Taxes | 15K | 17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -9K | -14K | 9K | 248K | 1.53M | 2.09M | 10.7M | -477K | -568K |
Working Capital Changes | -114K | 784K | 4.13M | 2.34M | -4.3M | -1.33M | 5.5M | 25.91M | -150K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -80K | 1.48M | 736K | 2.39M | 933K | 3.71M | 7.33M | -8.46M | 3.33M |
Cash from Investing | -1.12M | -3.5M | -843K | -87.44M | -81.35M | -45.49M | 104.13M | 52.7M | -56.7M |
Capital Expenditures | -1.12M | -3.5M | -888K | -398K | -755K | -845K | -1.13M | -122K | -84K |
CapEx % of Revenue | - | - | - | 7.89% | 19.8% | 55.34% | - | - | - |
Acquisitions | 0 | 0 | 0 | 87.04M | 80.59M | 44.65M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 45K | -87.04M | -80.59M | -44.65M | 0 | 0 | 0 |
Cash from Financing | 30.1M | 52.73M | 49.9M | 75.46M | 141.48M | 131.18M | 1.45M | 152.85M | 143.31M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1.2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 30.1M | 52.73M | 0 | 1.85M | 2.02M | 1.39M | 0 | 845K | 77K |
Net Change in Cash | 1.85M▲ 0% | 16.28M▲ 777.7% | 13.59M▼ 16.6% | -52.47M▼ 486.2% | -891K▲ 98.3% | 14.92M▲ 1774.4% | 8.53M▼ 42.8% | 122.26M▲ 1332.9% | 30K▲ 0% |
Free Cash Flow | -28.25M▲ 0% | -36.45M▼ 29.1% | -36.36M▲ 0.2% | -40.89M▼ 12.4% | -61.78M▼ 51.1% | -71.62M▼ 15.9% | -98.17M▼ 37.1% | -83.42M▲ 15.0% | -86.66M▲ 0% |
FCF Margin % | - | - | - | -810.97% | -1620.27% | -4689.98% | - | - | - |
FCF Growth % | - | -29.05% | 0.25% | -12.45% | -51.09% | -15.92% | -37.08% | 15.03% | 14.03% |
FCF per Share | -10.62 | -13.70 | -13.32 | -13.55 | -18.04 | -17.61 | -20.49 | -16.37 | -3.21 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.91x | 0.83x | 0.77x | 0.88x | 0.84x | 0.83x | 0.64x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 660K | 990K | 0 | 0 | 0 | 0 | 0 |
RAPT Key Ratios
RAPT Therapeutics, Inc. (RAPT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -4538.23% | -62.71% | -59.66% | -47.64% | -38.85% | -59.56% | -77.09% | -61.81% |
Return on Invested Capital (ROIC) | -34.63% | -41.67% | -106.43% | -42.97% | -34.09% | -59.25% | -155.69% | -87.1% |
Gross Margin | - | - | 100% | 100% | 100% | - | - | - |
Net Margin | - | - | -1049.03% | -1814.95% | -5490.37% | - | - | - |
Debt / Equity | 2.52x | - | - | - | 0.04x | 0.05x | 0.02x | 0.02x |
FCF Conversion | 0.91x | 0.83x | 0.77x | 0.88x | 0.84x | 0.83x | 0.64x | 0.82x |
Revenue Growth | - | - | - | -24.38% | -59.95% | -100% | - | - |
Related:RAPT Dividend History·RAPT Revenue History·RAPT Price History·RAPT P/E History·RAPT Financial Ratios·RAPT Institutional Holders
RAPT SEC Filings & Documents
RAPT Therapeutics, Inc. (RAPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
RAPT Frequently Asked Questions
RAPT Therapeutics, Inc. (RAPT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
RAPT Therapeutics, Inc. (RAPT) grew revenue by 0.0% over the past year. Growth has been modest.
RAPT Therapeutics, Inc. (RAPT) reported a net loss of $105.6M for fiscal year 2024.
Dividend & Returns
RAPT Therapeutics, Inc. (RAPT) has a return on equity (ROE) of -77.1%. Negative ROE indicates the company is unprofitable.
RAPT Therapeutics, Inc. (RAPT) had negative free cash flow of $86.7M in fiscal year 2024, likely due to heavy capital investments.